Mereo BioPharma Group PLC ADR (MREO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has a cash flow conversion efficiency ratio of -0.157x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.31 Million) by net assets ($46.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mereo BioPharma Group PLC ADR - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Mereo BioPharma Group PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MREO liabilities breakdown for a breakdown of total debt and financial obligations.
Mereo BioPharma Group PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Piolink Inc
KQ:170790
|
0.042x |
|
Jacques Bogart SA
PA:JBOG
|
-0.345x |
|
P&K Skin Research Center Co. Ltd
KQ:347740
|
0.021x |
|
Carlos Casado
BA:CADO
|
0.001x |
|
Classic Scenic Bhd
KLSE:7202
|
-0.022x |
|
Lokotech Group AS
OL:LOKO
|
-0.587x |
|
Mirza International Limited
NSE:MIRZAINT
|
0.020x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group PLC ADR (2015–2024)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group PLC ADR from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Mereo BioPharma Group PLC ADR stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.97 Million | $-32.83 Million | -0.539x | -28.79% |
| 2023-12-31 | $50.54 Million | $-21.13 Million | -0.418x | +55.97% |
| 2022-12-31 | $51.40 Million | $-48.82 Million | -0.950x | -1498.58% |
| 2021-12-31 | $119.01 Million | $-7.07 Million | -0.059x | -103.15% |
| 2020-12-31 | $-20.47 Million | $-38.62 Million | 1.887x | +267.05% |
| 2019-12-31 | $53.33 Million | $-60.22 Million | -1.129x | -59.95% |
| 2018-12-31 | $32.77 Million | $-23.14 Million | -0.706x | -37.23% |
| 2017-12-31 | $62.48 Million | $-32.15 Million | -0.515x | -48.83% |
| 2016-12-31 | $79.26 Million | $-27.40 Million | -0.346x | -424.01% |
| 2015-12-31 | $101.54 Million | $-6.70 Million | -0.066x | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more